Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics: Series C Funding Round
Torl Biotherapeutics has successfully raised $96M in Series C funding, reaching a valuation of $500M.
Company Overview
Antibody-based immunotherapies for cancer patients
Funding Details
The Series C round was led by Cormorant Asset Management, with participation from BVF Partners.
Company Information
- Headquarters: Los Angeles, CA
- Founded: 2019
- Employees: 90+
- Category: Biotech
Investment
Torl Biotherapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Cormorant Asset Management: Verified investor in Series C
- BVF Partners: Verified investor in Series C
Company Info
Investors (2)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Pick a plan and go live today. Change or cancel any time.
Get started